EHA 2022 | Update on QuANTUM-First: quizartinib + SOC chemotherapy & as continuation therapy in FLT3-ITD+ AML

FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) is one of the most common somatic mutations observed in patients with acute myeloid leukemia (AML) and is associated with poor outcomes. Over the last five years, two FLT3 inhibitors have been approved in AML: midostaurin in the first-line setting, and gilteritinib in the relapsed/refractory (R/R) setting. There are several other FLT3 inhibitors under investigation for AML, including quizartinib, an oral, potent, and highly selective type II FLT3 inhibitor. The ongoing randomized, double-blind, placebo-controlled Phase III study QuANTUM-First (NCT02668653) is evaluating whether the addition of quizartinib to standard induction and consolidation chemotherapy, and continued as a single-agent therapy, improves survival compared to chemotherapy alone in patients with newly diagnosed FLT3-ITD+ AML. In this video, Harry Erba, MD, PhD, Duke University, Durham, NC, shares the results of this study. Dr Erba explains that the study met its primary endpoint of overall survival (OS), with a median OS of 31.9 months in the quizartinib arm vs 15.1 months in the placebo arm. In addition, while grade ≥3 adverse events were similar in both arms, patients treated with quizartinib experienced greater rates of neutropenia and QT prolongation, and deaths occurred in 11.3% of patients treated with quizartinib vs 9.7% of patients treated with chemotherapy alone. Overall, the study showed that the addition of quizartinib led to a significant benefit in OS in FLT3-ITD+ AML and did not result in new safety signals. This press briefing was recorded at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.